Related Experiment Videos
Kips off to Myc: implications for TGF beta signaling
1Department of Cell Biology and Vanderbilt Cancer Center, Vanderbilt University Medical Center, Nashville, Tennessee 37232, USA.
Abstract:
Loss of sensitivity to the negative growth regulator transforming growth factor beta (TGF beta) is a feature of many different tumor types and is likely involved in tumor progression. In some cases this loss of sensitivity to TGF beta has been shown to be manifest in the absence of membrane-associated TGF beta receptor complexes, thus preventing initiation of antiproliferative signals from the cell surface. In others, loss of sensitivity to TGF beta-induced inhibitory signals has been attributed to loss of function of intracellular effectors of TGF beta-induced inhibitory signals due to mutation or allelic loss of effector genes and their products. The intracellular effectors of TGF beta inhibitory signals have been shown to be involved in the normal regulation of progression through the cell cycle, specifically during G1 phase. In this manner, elucidation of the mechanisms by which TGF beta inhibits cell growth not only helps us identify steps involved in tumor progression, but also allows us to better understand how cells regulate progression through the cell cycle.
Insights
Loss of sensitivity to transforming growth factor beta (TGF-β) is common in tumors. Understanding how TGF-β normally inhibits cell growth reveals key cancer progression and cell cycle regulation mechanisms.
Area of Science:
- Oncology
- Cell Biology
- Molecular Biology
Background:
- Loss of sensitivity to transforming growth factor beta (TGF-β) is a hallmark of many cancers, contributing to tumor progression.
- This loss of sensitivity can result from absent cell surface TGF-β receptor complexes or mutations in intracellular TGF-β signaling pathways.
Purpose of the Study:
- To investigate the mechanisms underlying TGF-β resistance in various tumor types.
- To elucidate the role of TGF-β signaling in cell cycle regulation, particularly during the G1 phase.
Main Methods:
- Analysis of TGF-β receptor expression on tumor cell membranes.
- Genetic analysis of intracellular TGF-β effector genes and their products.
- Studies on the regulation of cell cycle progression in response to TGF-β signaling.
Main Results:
- Identified two primary mechanisms of TGF-β insensitivity: absence of cell surface receptors and loss of function in intracellular effectors.
- Demonstrated that intracellular TGF-β effectors are critical for regulating G1 phase progression.
- Established a link between TGF-β signaling pathways and cell cycle control.
Conclusions:
- Understanding TGF-β resistance mechanisms is crucial for identifying novel therapeutic targets in cancer.
- Elucidating TGF-β's role in cell cycle regulation provides insights into fundamental biological processes and cancer development.